Zacks Research Has Positive Forecast for PBH Q1 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Analysts at Zacks Research boosted their Q1 2026 EPS estimates for Prestige Consumer Healthcare in a note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the company will earn $1.00 per share for the quarter, up from their prior estimate of $0.97. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q2 2026 earnings at $1.18 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.32 EPS, Q2 2027 earnings at $1.23 EPS, Q4 2027 earnings at $1.27 EPS and FY2027 earnings at $5.02 EPS.

PBH has been the subject of a number of other reports. Royal Bank of Canada raised shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Wall Street Zen raised shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, May 17th. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Canaccord Genuity Group increased their price target on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, Oppenheimer increased their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $84.99 on Monday. Prestige Consumer Healthcare has a 1 year low of $63.76 and a 1 year high of $90.04. The company has a market cap of $4.20 billion, a P/E ratio of 19.90, a PEG ratio of 2.69 and a beta of 0.44. The firm has a 50-day moving average of $83.58 and a 200 day moving average of $82.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The company had revenue of $296.52 million during the quarter, compared to analyst estimates of $289.36 million. During the same period in the prior year, the business posted $1.02 earnings per share. Prestige Consumer Healthcare’s revenue for the quarter was up 7.0% on a year-over-year basis.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in PBH. Kayne Anderson Rudnick Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $84,932,000. Raymond James Financial Inc. bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $42,593,000. Norges Bank bought a new stake in shares of Prestige Consumer Healthcare during the fourth quarter valued at approximately $40,009,000. Bessemer Group Inc. increased its position in shares of Prestige Consumer Healthcare by 10,053.1% during the fourth quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock valued at $23,041,000 after acquiring an additional 292,144 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Prestige Consumer Healthcare by 24.7% during the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock valued at $113,635,000 after acquiring an additional 261,537 shares in the last quarter. Institutional investors own 99.95% of the company’s stock.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the transaction, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.